Cutaneous angiosarcoma of the head and face: a single-center analysis of treatment outcomes in 43 patients in Japan

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: For a better understanding of angiosarcoma, we summarized our 30-year experience of conventional treatment outcomes before the era of molecular-targeted therapy. Methods: We conducted a retrospective review of our 43 patients with cutaneous angiosarcoma of the head and face, and investigated the prognostic factors including the treatment strategy. Disease-specific survival (DSS) and event-free survival (EFS) were estimated using the Kaplan–Meier method, together with multivariate analyses using the Cox proportional hazard regression model. Results: All patients were Japanese (25 males and 18 females), with a mean age of 72.1. For the initial treatment of the primary lesion, 34 patients underwent radiotherapy with or without taxanes (docetaxel and/or paclitaxel); only 6 patients underwent surgical excision. As the systemic adjuvant therapy, 19 patients were treated with taxanes and 15 with interleukin-2. Interestingly, patients who underwent the continued chemotherapy with taxanes had significantly prolonged DSS (5-year DSS, 57.0 vs. 19.6 %; median survival, 62.2 vs. 17.7 months; P = 0.0049) and EFS (5-year EFS, 34.9 vs. 5.6 %; median survival, 46.7 vs. 12.4 months; P = 0.0024) than the others. The continuous use of taxanes was also a prognostic factor in multivariate analyses. Neither radiotherapy nor surgical excision significantly influenced the patients’ outcome. Among five patients who survived more than 5 years, three underwent surgical excision of the primary tumor or lung metastasis. Conclusions: Our results suggest that continued chemotherapy with taxanes is important for patient survival.

Original languageEnglish
Pages (from-to)1387-1394
Number of pages8
JournalJournal of Cancer Research and Clinical Oncology
Volume142
Issue number6
DOIs
Publication statusPublished - Jun 1 2016

Fingerprint

Hemangiosarcoma
Japan
Head
Taxoids
Skin
Survival
Disease-Free Survival
docetaxel
Radiotherapy
Multivariate Analysis
Molecular Targeted Therapy
Drug Therapy
Paclitaxel
Proportional Hazards Models
Interleukin-2
Therapeutics
Neoplasm Metastasis
Lung

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{1d92cd80b95f475c81bfbdd6e71927cb,
title = "Cutaneous angiosarcoma of the head and face: a single-center analysis of treatment outcomes in 43 patients in Japan",
abstract = "Purpose: For a better understanding of angiosarcoma, we summarized our 30-year experience of conventional treatment outcomes before the era of molecular-targeted therapy. Methods: We conducted a retrospective review of our 43 patients with cutaneous angiosarcoma of the head and face, and investigated the prognostic factors including the treatment strategy. Disease-specific survival (DSS) and event-free survival (EFS) were estimated using the Kaplan–Meier method, together with multivariate analyses using the Cox proportional hazard regression model. Results: All patients were Japanese (25 males and 18 females), with a mean age of 72.1. For the initial treatment of the primary lesion, 34 patients underwent radiotherapy with or without taxanes (docetaxel and/or paclitaxel); only 6 patients underwent surgical excision. As the systemic adjuvant therapy, 19 patients were treated with taxanes and 15 with interleukin-2. Interestingly, patients who underwent the continued chemotherapy with taxanes had significantly prolonged DSS (5-year DSS, 57.0 vs. 19.6 {\%}; median survival, 62.2 vs. 17.7 months; P = 0.0049) and EFS (5-year EFS, 34.9 vs. 5.6 {\%}; median survival, 46.7 vs. 12.4 months; P = 0.0024) than the others. The continuous use of taxanes was also a prognostic factor in multivariate analyses. Neither radiotherapy nor surgical excision significantly influenced the patients’ outcome. Among five patients who survived more than 5 years, three underwent surgical excision of the primary tumor or lung metastasis. Conclusions: Our results suggest that continued chemotherapy with taxanes is important for patient survival.",
author = "Takamichi Ito and Hiroshi Uchi and Takeshi Nakahara and Gaku Tsuji and Yoshinao Oda and Akihito Hagihara and Masutaka Furue",
year = "2016",
month = "6",
day = "1",
doi = "10.1007/s00432-016-2151-2",
language = "English",
volume = "142",
pages = "1387--1394",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Cutaneous angiosarcoma of the head and face

T2 - a single-center analysis of treatment outcomes in 43 patients in Japan

AU - Ito, Takamichi

AU - Uchi, Hiroshi

AU - Nakahara, Takeshi

AU - Tsuji, Gaku

AU - Oda, Yoshinao

AU - Hagihara, Akihito

AU - Furue, Masutaka

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Purpose: For a better understanding of angiosarcoma, we summarized our 30-year experience of conventional treatment outcomes before the era of molecular-targeted therapy. Methods: We conducted a retrospective review of our 43 patients with cutaneous angiosarcoma of the head and face, and investigated the prognostic factors including the treatment strategy. Disease-specific survival (DSS) and event-free survival (EFS) were estimated using the Kaplan–Meier method, together with multivariate analyses using the Cox proportional hazard regression model. Results: All patients were Japanese (25 males and 18 females), with a mean age of 72.1. For the initial treatment of the primary lesion, 34 patients underwent radiotherapy with or without taxanes (docetaxel and/or paclitaxel); only 6 patients underwent surgical excision. As the systemic adjuvant therapy, 19 patients were treated with taxanes and 15 with interleukin-2. Interestingly, patients who underwent the continued chemotherapy with taxanes had significantly prolonged DSS (5-year DSS, 57.0 vs. 19.6 %; median survival, 62.2 vs. 17.7 months; P = 0.0049) and EFS (5-year EFS, 34.9 vs. 5.6 %; median survival, 46.7 vs. 12.4 months; P = 0.0024) than the others. The continuous use of taxanes was also a prognostic factor in multivariate analyses. Neither radiotherapy nor surgical excision significantly influenced the patients’ outcome. Among five patients who survived more than 5 years, three underwent surgical excision of the primary tumor or lung metastasis. Conclusions: Our results suggest that continued chemotherapy with taxanes is important for patient survival.

AB - Purpose: For a better understanding of angiosarcoma, we summarized our 30-year experience of conventional treatment outcomes before the era of molecular-targeted therapy. Methods: We conducted a retrospective review of our 43 patients with cutaneous angiosarcoma of the head and face, and investigated the prognostic factors including the treatment strategy. Disease-specific survival (DSS) and event-free survival (EFS) were estimated using the Kaplan–Meier method, together with multivariate analyses using the Cox proportional hazard regression model. Results: All patients were Japanese (25 males and 18 females), with a mean age of 72.1. For the initial treatment of the primary lesion, 34 patients underwent radiotherapy with or without taxanes (docetaxel and/or paclitaxel); only 6 patients underwent surgical excision. As the systemic adjuvant therapy, 19 patients were treated with taxanes and 15 with interleukin-2. Interestingly, patients who underwent the continued chemotherapy with taxanes had significantly prolonged DSS (5-year DSS, 57.0 vs. 19.6 %; median survival, 62.2 vs. 17.7 months; P = 0.0049) and EFS (5-year EFS, 34.9 vs. 5.6 %; median survival, 46.7 vs. 12.4 months; P = 0.0024) than the others. The continuous use of taxanes was also a prognostic factor in multivariate analyses. Neither radiotherapy nor surgical excision significantly influenced the patients’ outcome. Among five patients who survived more than 5 years, three underwent surgical excision of the primary tumor or lung metastasis. Conclusions: Our results suggest that continued chemotherapy with taxanes is important for patient survival.

UR - http://www.scopus.com/inward/record.url?scp=84961637028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961637028&partnerID=8YFLogxK

U2 - 10.1007/s00432-016-2151-2

DO - 10.1007/s00432-016-2151-2

M3 - Article

C2 - 27015673

AN - SCOPUS:84961637028

VL - 142

SP - 1387

EP - 1394

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 6

ER -